List view / Grid view
Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a…
Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a booster dose of Comirnaty® COVID-19 vaccine was safe and immunogenic.
Valneva and Pfizer’s Lyme disease vaccine VLA15 displayed a seroconversion…
Valneva and Pfizer’s Lyme disease vaccine VLA15 displayed a seroconversion rate of 100 percent for all OspA serotypes in Phase II study.
Pfizer’s RENOIR Phase III trial will evaluate the efficacy, immunogenicity…
Pfizer’s RENOIR Phase III trial will evaluate the efficacy, immunogenicity and safety of their respiratory syncytial virus (RSV) vaccine.
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has…
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has been published in a new scientific paper, demonstrating its 95 percent efficacy rate.
The BNT162b2 mRNA-based vaccine produced by Pfizer and BioNTech will enter…
The BNT162b2 mRNA-based vaccine produced by Pfizer and BioNTech will enter Phase have II/III clinical trials to test its safety and efficacy against COVID-19.
